Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
Sponsor: Columbia University
A PHASE1 clinical study on Cannabis Use Disorder and Dual Diagnosis, this trial is completed. The trial is conducted by Columbia University and has accumulated 13 data snapshots since 2014. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Jan 2026 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2021 — Jan 2022 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 8 earlier versions
-
Mar 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
May 2019 — May 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Apr 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Columbia University
- Dartmouth-Hitchcock Medical Center
- Harvard Medical School (HMS and HSDM)
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Nathan Kline Institute for Psychiatric Research
- National Institute on Drug Abuse (NIDA)
- University of Vermont
For direct contact, visit the study record on ClinicalTrials.gov .